(RTTNews) - Oramed Pharmaceuticals Inc. (ORMP), a firm focused on oral drug delivery platforms, on Tuesday announced positive results from the Phase 2 trial which examined the safety and efficacy of its oral insulin candidate, ORMD-0801, with 8 mg twice daily dosing.
The trial was aimed to reduce liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis or NASH.
The trial also evaluated the effectiveness of ORMD-0801 in reducing liver fat content over the 12-week treatment period by observing several independent measures.
ORA-D-N02 is a Phase 2 double-blind, randomized, placebo-controlled, multicenter trial to assess the safety and efficacy of Oramed's oral insulin candidate, ORMD-0801, to reduce liver fat content in T2D patients with NASH.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
